Abstract: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.

Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.

Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion from said tumour cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

Abstract: The present invention relates to polypeptides for use in suppressing cancer and cancer disorders. The treatment employs use of a non-cytotoxic protease, which is targeted to the cancer cell, and, when so delivered, the protease is internalised and inhibits secretion from the cancer cell.

Abstract: The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumor cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalized and inhibits secretion from said tumor cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

Abstract: A method for controlling a heat recovery device in an internal combustion engine, in particular, for a motor vehicle. The heat recovery device is provided with a circuit for a working medium having an evaporator of an expansion machine that is arranged in an exhaust gas flow path of the internal combustion engine, a condensor, an expansion tank, and a feed pump. The working temperature of the working medium is controlled by varying the mass flow of the working fluid as a function of at least one operating parameter. A setpoint value of the working medium mass flow of an exhaust gas flow path of an exhaust gas tract and/or an exhaust gas recirculation line is calculated on the basis of a base setpoint value for the working medium mass flow. The base setpoint value for the working medium mass flow is at least a function of the exhaust gas temperature, preferably upstream of the evaporator, and of the exhaust gas mass flow in the exhaust gas flow path.

Abstract: An apparatus extracts water from the air using a single circuit of gas containing a compressor, a cooling element, a heat exchanger and an ion source, where a single stream of air is used to provide water and to pre-cool the inlet air.

Abstract: The system for installing shower walls includes a pressure transfer member for urging a shower wall against a back up support during bonding of the shower wall to the support. An adjustable force development device engages the pressure transfer member to force the pressure transfer member against the shower wall. A support member engages the pressure transfer member when the force development device exerts a predetermined force against the shower wall. A fixation device holds the support member to maintain the pressure transfer position of the pressure transfer member. The fixation device includes a cam that moves a shower wall into a tight corner fit with an adjacent shower wall.

Abstract: A composite material comprises magnetic particles dispersed in electrically insulating material. The magnetic particles have an aspect ratio greater than 1 (preferably greater than 10) and a concentration sufficiently high to produce negative permeability. The magnetic particles may be magnetic flakes of reduced carbonyl iron of average diameter 50 ?m, average thickness 1 ?m and aspect ratio 50, the magnetic flakes being at least 25% by volume of the composite material. The magnetic flakes may be aligned to produce enhanced permeability. The electrically insulating material may be paraffin wax, particulate PTFE, or another polymer. To control permittivity, the composite material may include an electrically conducting component such as graphite or conductive coatings upon the magnetic flakes.

Abstract: An end effector assembly for use with an instrument for sealing vessels and cutting vessels includes a pair of opposing first and second jaw members which are movable relative to one another from a first spaced apart position to a second position for grasping tissue therebetween. Each jaw member includes an electrically conductive tissue contacting surface connected to an electrosurgical energy source. At least one of the jaw members includes an electrically conductive cutting element disposed within an insulator defined in the jaw member. At least one channel is included in the insulator which is configured to deliver fluid between the jaw members.

Abstract: A system for the structural monitoring of blades 1 on a wind turbine. Each blade 1 has respective optical fiber bragg grating sensors 5. The system has a number of input connectors, which connect to the strain sensors 5 of respective blades 1. A single output connector connects to a data processing device 3 which processes signals from the strain sensors 5. The input connectors each have a signal path to the output connector that is different in length to the signal path from the other input connectors, such that signals from a given blade 1 can be identified at the data processing device 3 by the time of arrival of the signals. The system has the advantage that the each of the blades 1, including the sensors attached to it or embedded within it can be identical and therefore interchangeable.

Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.

Abstract: This invention relates to the field of an electromagnetic (EM) field shielding paint compositions, in particular, those capable of providing substantially non metallic finish. The paint composition finds particular use in attenuating EM signals that may be used to carry data between communication devices, especially mobile phone and wi-fi devices. EM field shielding paints are typically available in jet-black or bright metallic finishes and usually possess limited scratch & abrasion resistance. The paint composition provides a one-pot solution to furnish a composition which has the visual appearance of a domestic type paint i.e. one with a non-metallic finish, with the ability to shield electromagnetic radiation. The composition comprises a supported metallic flake and a pigment, which have been provided in a narrowly defined range to furnish a desirable non-metallic appearance and possess electromagnetic shielding properties.

Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.

Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acids encoding the fusion proteins, methods of preparing same and uses thereof are also described.

Abstract: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.

Abstract: It is desirable to achieve a co-incident investigative kV source for a therapeutic MV source—a so-called “beams-eye-view” source. It has been suggested that bremsstrahlung radiation from an electron window be employed; we propose a practical structure for achieving this which can switch easily between a therapeutic beam and a beam-eye-view diagnostic beam capable of offering good image resolution. Such a radiation source comprises an electron gun, a pair of targets locatable in the path of a beam produced by the electron gun, one target of the pair being of a material with a lower atomic number than the other, and an electron absorber insertable into and withdrawable from the path of the beam. In a preferred form, the electron gun is within a vacuum chamber, and the pair of targets are located at a boundary of the vacuum chamber. The lower atomic number target can be Nickel and the higher atomic number target Copper and/or Tungsten.